CRBN Ligand Composition for Selective PROTAC Protein Degradation
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current CRBN-based protein degradation-targeting chimeras (PROTACs) face limitations in the design and synthesis of novel ligands, which can induce additional degradation of domain proteins, hindering their effectiveness in treating diseases.
Innovation Solution
Development of novel CRBN ligands and corresponding PROTAC molecules, represented by Formula I, which include specific substituents and functional groups to enhance targeted protein degradation.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If existing CRBN-based PROTACs are used for protein degradation, then cancer and other diseases can be treated through ubiquitin-proteasome pathway activation, but additional degradation of domain proteins occurs due to inherent effects of CRBN ligands on their target sites
Solution Approach 1:
The patent applies local quality by introducing specific substituents at defined positions (R31-R40) in the CRBN ligand structure to achieve selective binding to CRBN while avoiding off-target effects on domain proteins. The formula I structure allows localized chemical modification at specific sites to optimize specificity.
Solution Approach 2:
The patent employs parameter changes by systematically varying chemical parameters (substituents at R31-R40 positions) to optimize the ligand's binding affinity and specificity. By changing chemical parameters at specific locations, the patent achieves selective protein degradation without degrading domain proteins.
2Reliability
If novel CRBN ligands are designed to improve specificity, then degradation of domain proteins is reduced, but the complexity of ligand design and synthesis increases
Solution Approach 1:
The patent applies segmentation by dividing the CRBN ligand into distinct functional regions with specific substituents at defined positions (R31-R40). This modular approach allows independent optimization of each region's properties while maintaining overall ligand functionality, simplifying the design process.
Solution Approach 2:
The patent employs universality by creating a general formula I structure that can accommodate multiple substituent types at defined positions. This universal framework allows a single design paradigm to generate multiple specific ligands for different applications, reducing overall design complexity.
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The novel CRBN ligands and PROTACs provide improved specificity and efficacy in protein degradation, addressing the limitations of existing technologies and enhancing therapeutic potential.
Implementation Method 1
this complex mediates proteolysis through the ubiquitin-proteasome pathway
Data Source
AI summary
The present invention provides a novel human cerebellar protein (CRBN) E3 ubiquitin ligase inhibitor, capable of being used to prepare a PROTAC molecule. The CRBNE3 ubiquitin ligase inhibitor and the PROTAC molecule can be used to treat cancer and other diseases.